Novel inhaled pulmonary vasodilators in adult cardiac surgery: a scoping review.
Navindra David, Sameer Lakha, Samantha Walsh...
https://pubmed.ncbi.nlm.nih.gov/38782851/Actively Recruiting
Led by Xijing Hospital · Updated on 2026-05-29
3650
Participants Needed
3
Research Sites
52 weeks
Total Duration
Cardiac surgery, often performed worldwide with the use of cardiopulmonary bypass CPB, remains a high-risk procedure due to complications such as acute kidney injury, respiratory failure, myocardial infarction, stroke, and cognitive dysfunction. Researchers are evaluating inhaled nitric oxide NO therapy as a selective pulmonary vasodilator to manage pulmonary hemodynamics and reduce life-threatening complications in high-risk cardiac surgery patients. This large multicenter randomized controlled trial aims to confirm the benefits of NO in reducing death and major adverse events after cardiac surgery with CPB. In this Phase III, double-blind, multicenter study, participants are randomly assigned to receive either inhaled NO gas or a control gas during and after cardiac surgery with CPB. The NO group receives 80 parts per million ppm of NO during CPB via the oxygenator, followed by 40-80 ppm of NO through the ventilator for up to 6 hours after ICU admission or until extubation. The control group receives standard care with 80 ppm nitrogen N2 added to the gas mixture or air without NO. The study investigates the effects of NO on reducing major adverse events and the need for intensive life support. Participants are monitored through 30 days after surgery for a composite outcome of death and major adverse events requiring intensive life support. Assessments include the number and incidence of major adverse events, acute kidney injury within 7 days, length of mechanical ventilation, ICU stay, hospital stays, and mortality up to one year. Additional evaluations involve organ-specific scores, hemolysis markers, and safety monitoring. The total participation duration includes follow-up assessments up to one year after surgery to evaluate long-term outcomes and safety.
CONDITIONS
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
C
Chong Lei, M.D., & phd
Z
ziyu Zheng, ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xijing Hospital
Lead Sponsor
Nikolay O. Kamenshchikov., M.D., Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Inhaled Nitric Oxide (iNO) | Standard Care (Placebo Control) |
|---|---|---|
| What it is | Inhaled nitric oxide gas administered through the oxygenator during cardiopulmonary bypass, then via ventilator after surgery for up to 6 hours or until extubation. | Placebo treatment: standard care with nitrogen gas added to the mixture through the same circuits or an inactive NO generator; no active inhaled nitric oxide given. |
| Role in the trial | Assesses whether adding inhaled nitric oxide can reduce death or major adverse events requiring intensive life support after adult cardiac surgery with cardiopulmonary bypass. | Serves as the randomized control group, receiving no therapeutic inhaled nitric oxide. Assesses the effect of standard care alone for comparison. |
| Primary use or purpose | Investigational therapy to reduce postoperative death or major complications (such as need for intensive life supports) after cardiac surgery requiring cardiopulmonary bypass. | Standard care serves as the control to measure whether inhaled nitric oxide provides additional benefit. |
| How it is given or performed | Nitric oxide is given at 80 parts per million (ppm) during cardiopulmonary bypass via the oxygenator; after bypass, it is inhaled (40–80 ppm) through the ventilator for up to 6 hours post-surgery or until extubation. | Nitrogen gas (or inactive NO synthesis) is administered through the same equipment as a placebo, maintaining blinding. |
| Evidence status | Prior small randomized trials and meta-analyses suggest inhaled nitric oxide may improve some postoperative outcomes (e.g., reducing acute kidney injury, improving oxygenation), but overall evidence for reduction in major adverse events and mortality is inconclusive. Larger studies are ongoing. | Outcomes with current standard care are well-documented; the trial will help establish whether adding inhaled nitric oxide provides clinical benefit above usual perioperative management. |
| Important limitations | Clinical benefits for major adverse outcomes and mortality are unproven; optimal iNO dose, timing, and target population remain uncertain. Effects may vary across surgery types and perioperative practices. | Rates of major adverse events after cardiac surgery are still considerable, and existing standard care does not target postoperative organ injury risk in a specific way. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgery day and up to 6 hours after ICU admission or until extubation
Participants undergo cardiac surgery with cardiopulmonary bypass and receive inhaled nitric oxide gas or control gas during surgery and up to 6 hours after ICU admission or until extubation, whichever comes first.
1 surgery day visit and continuous treatment during ICU stay
Duration - Up to 1 year after surgery
Participants are monitored for major adverse events, kidney function, ventilation duration, ICU and hospital stay length, and survival up to 1 year after surgery.
Visits and assessments at multiple time points including 7 days, 30 days, 90 days, and 1 year post-surgery
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Navindra David, Sameer Lakha, Samantha Walsh...
https://pubmed.ncbi.nlm.nih.gov/38782851/Dominik J Schaer, Christian A Schaer, Rok Humar...
https://pubmed.ncbi.nlm.nih.gov/39159287/Chong Lei, Lorenzo Berra, Emanuele Rezoagli...
https://pubmed.ncbi.nlm.nih.gov/29932345/Yun Yan, Nikolay Kamenshchikov, Ziyu Zheng...
https://pubmed.ncbi.nlm.nih.gov/38556145/Nikolay O Kamenshchikov, Yana J Anfinogenova, Boris N Kozlov...
https://pubmed.ncbi.nlm.nih.gov/32718702/Kai Liu, Huan Wang, Shen-Ji Yu...
https://pubmed.ncbi.nlm.nih.gov/33987295/Karam Azem, Denis Novakovsky, Boris Krasulya...
https://pubmed.ncbi.nlm.nih.gov/39037709/Stefan P Janssens, Jan Bogaert, Jaroslaw Zalewski...
https://pubmed.ncbi.nlm.nih.gov/29800130/Kamrouz Ghadimi, Jhaymie L Cappiello, Mary Cooter Wright...
https://pubmed.ncbi.nlm.nih.gov/37401479/Mohamed Abouzid, Yara Roshdy, John Magdy Daniel...
https://pubmed.ncbi.nlm.nih.gov/37650923/Xijing Hospital
Lead Sponsor
Nikolay O. Kamenshchikov., M.D., Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborating Sponsor